The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping
复制标题
DOI：
10.1016/j.breast.2014.02.013
复制
发表时间：
2014-06-01
期刊：
影响因子：
3.9
通讯作者：
Fountzilas, George
中科院分区：
文献类型：
--
作者：
Lakis, Sotiris;Kotoula, Vassiliki;Fountzilas, George
雄激素受体(AR)是乳腺癌潜在的预后标志物和治疗靶点。我们评估了在辅助性环境中接受治疗的高危乳腺癌患者AR蛋白的表达。肿瘤分为腔性癌(ER+/PGR+/-/AR+/-)、分子顶分泌型(MAC，[ER-/PGR-/AR+])和激素受体阴性癌(HR-，[ER-/PGR-/AR-])。亚型评估预后和紫杉烷治疗。高组织学分级(p<；0.001)和增殖增强(p=0.001)在MAC和HR阴性的肿瘤中比在管腔肿瘤中更常见。患有MAC的患者的预后与鲁米那组相似，而HR阴性的患者复发和死亡的风险增加。在含紫杉烷的治疗中，MAC结果是有利的；这在对总存活率(HR0.31，95%CI0.13-0.74，交互作用p=0.035)和复发时间的趋势(p=0.15)的多变量分析中仍然显著。综上所述，乳腺癌AR相关亚型可作为判断预后和选择最佳治疗方案的参考指标。(C)2014爱思唯尔有限公司。保留所有权利。
The Androgen Receptor (AR) is a potential prognostic marker and therapeutic target in breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the adjuvant setting. Tumors were subtyped into luminal (ER+/PgR +/-/AR +/-), molecular apocrine (MAC, [ER-/PgR-/AR+]) and hormone receptor negative carcinomas (HR-negative, [ER-/PgR-/AR-]). Subtyping was evaluated with respect to prognosis and to taxane therapy. High histologic grade (p < 0.001) and increased proliferation (p = 0.001) more often appeared in MAC and HR-negative than in luminal tumors. Patients with MAC had outcome comparable to the luminal group, while patients with HR-negative disease had increased risk for relapse and death. MAC outcome was favorable upon taxane-containing treatment; this remained significant upon multivariate analysis for overall survival (HR 0.31, 95% CI 0.13-0.74, interaction p = 0.035) and as a trend for time to relapse (p = 0.15). In conclusion, AR-related subtyping of breast cancer may be prognostic and serve for selecting optimal treatment combinations. (C) 2014 Elsevier Ltd. All rights reserved.